Cima and Tetraneuron sign a strategic agreement to advance gene therapies for neurodegenerative diseases
The agreement establishes a collaborative framework to promote research into Parkinson's disease, Alzheimer's disease, and age-related cognitive decline.
February 17, 2026
Cima and Tetraneuron, a Spanish biotechnology company focused on gene therapies for neurodegenerative diseases, announced the signing of a strategic collaboration agreement aimed at advancing novel therapeutic approaches for neurodegenerative disorders.
The agreement establishes a collaborative framework to advance research and generate scientific evidence around the PLA2G4E target, with potential therapeutic applications in Parkinson’s disease, Alzheimer’s disease and age-related cognitive decline, as well as to explore its future clinical translation through AAV-based gene therapies.
Bridging academic excellence and biotech development
Under the terms of the agreement, CIMA Universidad de Navarra will contribute its scientific leadership and advanced biomedical research capabilities, while Tetraneuron will bring its expertise in preclinical development, regulatory strategy and clinical translation, with the shared objective of accelerating the transformation of scientific discoveries into therapeutic solutions with real impact for patients.
The collaboration includes the development of joint research projects, the generation of preclinical data, and the exploration of future licensing opportunities to support progression towards regulatory and clinical development stages.
“This agreement strengthens our strategy to build a robust pipeline grounded in scientific excellence. Collaborating with CIMA allows us to deepen a new biological axis with high therapeutic potential and to expand our ambition beyond Alzheimer’s disease,” said Ángel Lucio Pereira, CEO of Tetraneuron.
“Partnering with Tetraneuron enables us to advance the translational potential of our research and to contribute to the development of innovative gene therapy approaches in areas of high unmet medical need,” said Lucía Vanrell, Head of Tech Transfer and Innovation at CIMA.
Strengthening the pipeline with a long-term vision
The agreement is part of Tetraneuron’s broader strategy to build a high-impact gene therapy platform focused on neurodegeneration, complementing its lead Alzheimer’s disease programme with new assets grounded in emerging science. For CIMA, the collaboration represents an opportunity to maximise the clinical and societal impact of academic research, reinforcing the organisation’s profile as an international leader in neuroscience and translational medicine.